20. November 2009 23:40
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
[More]
eb34af81-8141-4574-b270-52cb5d01cd03|0|.0
Posted in: Child Health News | Pharmaceutical News
Tags: Abilify, Antidepressant, Antipsychotic, Autism, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, Cell, Cerebrovascular Disease, Constipation, Creatinine, Dehydration, Dementia, Depression, Diabetes, Diabetes Mellitus, Dystonia, Exercise, Heart Failure, Hyperglycemia, Hypersensitivity, Insomnia, Leukopenia, Lipids, Nausea, Neutropenia, New Drug Application, Obesity, Pediatrics, Pneumonia, Psychosis, Schizophrenia, Speech, Stroke, Tardive Dyskinesia, Urticaria, Vomiting
20. November 2009 11:10
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
[More]
20. November 2009 08:52
Merck & Co., Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of ELONVA® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program.
[More]
20. November 2009 00:59
Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc., today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC).
[More]
19. November 2009 03:13
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
[More]
7169822c-90e7-4db1-bb27-26e0162bbe54|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cancer, Cell, Chemotherapy, Chronic Lymphocytic Leukemia, Cough, Cyclophosphamide, Headache, Hepatitis B, Leukemia, Lymphoma, MabThera, Methotrexate, Multiple Sclerosis, Nausea, Rheumatoid Arthritis, Rituximab, Virus
19. November 2009 00:22
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
[More]
9f19f465-9b09-4558-8717-5dc5f9c0f5b8|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Anorexia, Biopsy, Biotechnology, Cancer, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diarrhea, Erlotinib, Head and Neck Cancer, Hepatocellular Carcinoma, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Pfizer, Radiotherapy, Small Cell Lung Cancer, Squamous Cell Carcinoma, Vomiting
18. November 2009 10:31
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
[More]
a61a65ac-e150-48dc-bb4d-d91e79fc3c1c|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cancer, Cell, Constipation, Cough, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Peripheral Neuropathy, Pneumonia, Thrombocytopenia, Ubiquitin, Vomiting
18. November 2009 08:52
Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash.
[More]
18. November 2009 07:34
Pfizer Canada accepted the Prix Galien Canada 2009 Innovative Product Award for CHAMPIX (varenicline tartrate), the first prescription treatment for smoking cessation in adults specifically designed to target nicotine addiction. The award was presented last night at a gala in Ottawa recognizing excellence in pharmaceutical research.
[More]
fca250df-5848-4337-8a95-05b6cd411164|0|.0
Posted in: Pharmaceutical News
Tags: Abstinence, Anxiety, Brain, Cardiovascular Disease, Constipation, Drug Abuse, Morphine, Nausea, Nicotine, Nicotine Addiction, Pfizer, Smoking, Smoking Cessation, Tobacco, Vomiting
18. November 2009 06:35
In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information.
[More]
18. November 2009 04:30
NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.
[More]
fb71fcf5-7a8a-4a34-a06b-4ea9eafc39f8|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Alopecia, Antihistamine, Back Pain, Cancer, Diarrhea, Docetaxel, Edema, Liposome, Nausea, Neuropathy, Neutropenia, Peripheral Neuropathy, Prostate Cancer, Taxotere
18. November 2009 01:57
Family caregivers can significantly reduce suffering in cancer patients at home through use of simple touch and massage techniques. These findings were recently reported at the 6th International Conference of the Society for Integrative Oncology.
[More]
17. November 2009 05:02
To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.
[More]
ac48c877-eb35-45fc-9d99-0eb9b9d6de31|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Acetylation, Adenosine, Amino Acid, Anemia, Angiogenesis, Autophagy, Blood Pressure, Breast Cancer, Cancer, Cediranib, Cell, Chemotherapy, Colorectal Cancer, Diarrhea, DNA, Gene Expression, Hematology, Leukemia, Myeloid Leukemia, Nausea, Oncology, Ovarian Cancer, Radiotherapy, Stem Cell, Stress, Vomiting
17. November 2009 03:36
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.
[More]
52d6ae04-8005-4377-aa8f-72b645331f28|0|.0
Posted in: Women's Health News | Pharmaceutical News
Tags: Abdominal Pain, Angiogenesis, Anthracycline, Antibody, Avastin, Back Pain, Bevacizumab, Biotechnology, Birth Control, Blood Pressure, Blood Vessel, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Congestive Heart Failure, Dehydration, Dermatitis, Diarrhea, Docetaxel, Fertility, Fistula, Headache, Heart Failure, Low Blood Pressure, Nausea, Nervous System, Paclitaxel, Pregnancy, Stroke, VEGF, Vomiting, Wound Healing
16. November 2009 23:15
Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).
[More] 
Subscribe